Serum albumin-20K growth hormone fusion protein
US10968267B2 · kind B2 · utility
0Cited by
14References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2018 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Feb 5, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.